Approval of US Pilot Clinical Trial to Evaluate AclarusDx(™), the ExonHit Therapeutics Inc. Investigational Test for Alzheimer’s Disease Diagnosis

Published: Oct 26, 2011

PARIS--(BUSINESS WIRE)--Regulatory News:

Exonhit (Paris:ALEHT) announced today the Institutional Review Board (IRB) approval of Exonhit sponsored pilot clinical trial aimed at evaluating the performance of AclarusDx™, a blood based investigational diagnostic test, in US-based patients suffering from memory impairment and newly referred to a reference Memory Center for Alzheimer’s Disease (AD) diagnostic workup. This study will be conducted by the Cleveland Clinic Lou Ruvo Center for Brain Health.

Back to news